We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP - Free Report) . Shares have added about 0.8% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Q3 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics incurred a third-quarter 2024 loss of $1.01 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.33. In the year-ago period, the company had incurred a loss of $1.41 per share.
Total revenues, though negligible, were entirely from grant revenues, which were $0.6 million in the quarter. The reported figure significantly missed the Zacks Consensus Estimate of $6.4 million. The company did not generate revenues during the year-ago period.
Quarter in Detail
In the reported quarter, research and development expenses fell 9% year over year to $82.2 million. This was due to reduced variable external research and manufacturing costs.
General and administrative expenses declined 5% year over year to $17.4 million in the quarter.
Collaboration expenses in the quarter were $11.2 million, down 52% year over year. The downside was primarily due to the time it took to reach the deferral limit on costs related to the Casgevy program.
As of Sept. 30, 2024, the company had cash, cash equivalents, marketable securities and accounts receivables of $1.9 billion compared with $2.0 billion as of June 30, 2024.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
At this time, CRISPR Therapeutics has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CRISPR Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
CRISPR Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Krystal Biotech, Inc. (KRYS - Free Report) , has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended September 2024.
Krystal Biotech reported revenues of $83.84 million in the last reported quarter, representing a year-over-year change of +879.4%. EPS of $0.91 for the same period compares with -$0.67 a year ago.
For the current quarter, Krystal Biotech is expected to post earnings of $1.25 per share, indicating a change of +316.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.7% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Krystal Biotech. Also, the stock has a VGM Score of B.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP - Free Report) . Shares have added about 0.8% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Q3 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics incurred a third-quarter 2024 loss of $1.01 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.33. In the year-ago period, the company had incurred a loss of $1.41 per share.
Total revenues, though negligible, were entirely from grant revenues, which were $0.6 million in the quarter. The reported figure significantly missed the Zacks Consensus Estimate of $6.4 million. The company did not generate revenues during the year-ago period.
Quarter in Detail
In the reported quarter, research and development expenses fell 9% year over year to $82.2 million. This was due to reduced variable external research and manufacturing costs.
General and administrative expenses declined 5% year over year to $17.4 million in the quarter.
Collaboration expenses in the quarter were $11.2 million, down 52% year over year. The downside was primarily due to the time it took to reach the deferral limit on costs related to the Casgevy program.
As of Sept. 30, 2024, the company had cash, cash equivalents, marketable securities and accounts receivables of $1.9 billion compared with $2.0 billion as of June 30, 2024.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
At this time, CRISPR Therapeutics has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, CRISPR Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
CRISPR Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Krystal Biotech, Inc. (KRYS - Free Report) , has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended September 2024.
Krystal Biotech reported revenues of $83.84 million in the last reported quarter, representing a year-over-year change of +879.4%. EPS of $0.91 for the same period compares with -$0.67 a year ago.
For the current quarter, Krystal Biotech is expected to post earnings of $1.25 per share, indicating a change of +316.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.7% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Krystal Biotech. Also, the stock has a VGM Score of B.